2012
Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
Bordeaux JM, Cheng H, Welsh AW, Haffty BG, Lannin DR, Wu X, Su N, Ma XJ, Luo Y, Rimm DL. Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen. PLOS ONE 2012, 7: e36559. PMID: 22606272, PMCID: PMC3350519, DOI: 10.1371/journal.pone.0036559.Peer-Reviewed Original Research
2011
Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved Utility
Bartlett J, Rea D, Rimm DL. Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved Utility. Journal Of Clinical Oncology 2011, 29: 3715-3716. PMID: 21810678, DOI: 10.1200/jco.2011.37.3704.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsFemaleHumansPatient SelectionReceptors, EstrogenReceptors, ProgesteroneLoss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure. Journal Of Clinical Oncology 2011, 29: 2448-2458. PMID: 21576635, PMCID: PMC3675698, DOI: 10.1200/jco.2010.30.3552.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCohort StudiesDisease ProgressionDisease-Free SurvivalDrug Resistance, NeoplasmEstrogen Receptor ModulatorsFemaleHumansLymphatic MetastasisMiddle AgedNeoplasm ProteinsNuclear ProteinsPhosphorylationPhosphotyrosinePrognosisProtein Processing, Post-TranslationalSTAT5 Transcription FactorSurvival AnalysisTreatment FailureTumor Suppressor ProteinsYoung AdultConceptsNode-negative breast cancerCancer-specific survivalIndependent prognostic markerBreast cancerWhole tissue sectionsTherapy failurePrognostic markerTissue microarrayPathologist scoringMultivariate analysis patientsSystemic adjuvant therapyAdjuvant hormone therapyMarker of prognosisPoor clinical outcomeUseful predictive markerPredictors of responseNormal breast epitheliumTissue sectionsCohort IVAdjuvant therapyHormone therapyAnalysis patientsClinical outcomesDuctal carcinomaProspective studyGefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study. Clinical Cancer Research 2011, 17: 1147-1159. PMID: 21220480, PMCID: PMC3074404, DOI: 10.1158/1078-0432.ccr-10-1869.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsDrug-Related Side Effects and Adverse ReactionsErbB ReceptorsFemaleGefitinibHumansMiddle AgedNeoplasms, Hormone-DependentPlacebosQuinazolinesReceptor, ErbB-2Receptors, EstrogenSignal TransductionTamoxifenTreatment OutcomeConceptsAdjuvant aromatase inhibitorsMetastatic breast cancerBreast cancerHormone receptor-positive metastatic breast cancerPositive metastatic breast cancerRandomized phase II studyRandomized phase II trialClinical benefit ratePhase II studyPhase II trialProgression-free survivalStratum 1Epidermal growth factor receptor inhibitor gefitinibFurther investigationAdjuvant tamoxifenImproved PFSPFS HRAI therapyII studyII trialMetastatic diseaseAppropriate patientsPredictive biomarkersPrimary tumorTamoxifen resistance